Alex Martínez‐Martí
YOU?
Author Swipe
View article: Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement Open
Updated suggestions were developed for the most relevant situations in the treatment of patients with early-stage and locally advanced NSCLC. These suggestions will support clinical decision-making in daily practice. This paper presents th…
View article: Insights on Oligometastatic Non-Small-Cell Lung Cancer
Insights on Oligometastatic Non-Small-Cell Lung Cancer Open
Oligometastatic non-small-cell lung cancer (OMD-NSCLC) has emerged as a biologically and clinically distinct subtype of advanced disease, characterized by limited metastatic burden and a more indolent course. In this narrative review, we e…
View article: Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer Open
Importance The PACIFIC trial established durvalumab as the standard-of-care therapy for unresectable, stage III non–small cell lung cancer (NSCLC) without progression following concurrent chemoradiotherapy (cCRT). Novel immunotherapy combi…
View article: Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) Open
Perioperative chemoimmunotherapy has significantly improved survival rates for non-small cell lung cancer (NSCLC). However, current tissue biomarkers remain inadequate, underscoring the need for more sensitive and accessible alternatives t…
View article: Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer
Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer Open
PURPOSE Adjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor ( EGFR )–mutated non–small cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes. METH…
View article: Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial Open
IMpower010 (ClinicalTrials.gov identifier: NCT02486718 ) previously showed that atezolizumab improved disease-free survival (DFS) versus best supportive care (BSC) after adjuvant chemotherapy in patients with resected non–small cell lung c…
View article: BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives
BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives Open
Pleural mesothelioma (PM) is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy hav…
View article: Legends to supplementary figures and tables from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Legends to supplementary figures and tables from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Contains the legends for all the supplementary figures and legends
View article: Supplementary methods and materials from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary methods and materials from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary methods and materials
View article: Supplementary Table S2 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary Table S2 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary Table S2
View article: Supplementary figures from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary figures from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary Figure 1, 2,3 4,5
View article: Supplementary Table 1 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary Table 1 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary Table 1A, B, C, D and E
View article: Data from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Data from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Purpose: We aimed to maximize the performance of detecting genetic alterations in lung cancer using high-throughput sequencing for patient-derived xenografts (PDXs).Experimental Design: We undertook an integrated RNA and whole-exome sequen…
View article: Supplementary Table S3 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Supplementary Table S3 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition Open
Supplementary Table S3
View article: Supplementary table S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary table S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Table S4: Differentially expressed genes between High and Low Top 1% clonal space tumors.
View article: Figure S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Figure S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
PFS and OS survival stratified by pre-treatment evenness, TMB, and PD-L1. Correlation between tissue evenness and TMB or PD-L1. Mutations and pre-treatment tissue top 1% clonal space.
View article: Figure S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Figure S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Tissue TCR evenness and top 1% clonal space are independent of reported read counts, clones identified, and tissue origing.
View article: Supplementary file S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary file S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
TCR Clone lists identified in pre-treatment samples
View article: Supplementary table S1, S2, and S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary table S1, S2, and S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Table S1: Patients' samples and techniques. Table S2: Summary of available samples. Table S3: Canonical somatic tumor mutations and top 1%.
View article: Supplementary file S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary file S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
TCR Clone lists identified in post-treatment samples
View article: Figure S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Figure S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Stability of evenness and top 1% across technical replicates and Clonal reproducibility
View article: Data from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Data from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Purpose:Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non–small cell lung cancer (NSCLC).Experimental Design:In this…
View article: Supplementary table S5 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Supplementary table S5 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Table S5: Gene Ontology enrichment analysis of differentially expressed genes between High and Low Top 1% clonal space tumors.
View article: Figure S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Figure S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy Open
Clonal space occupied by shared or newly emergent clones top 1% post-T clones in PBMCs at pre- and post-treatment timepoints.
View article: Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial Open
Bristol-Myers Squibb, Spanish Ministry of Science, Instituto de Salud Carlos III, European Union.
View article: Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer Open
Background Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to immunotherapy. However, there is no data o…
View article: Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study
Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study Open
Background Factors to accurately stratify patients with early-stage non-small cell lung cancer (NSCLC) in different prognostic groups are still needed. This study aims to investigate 1) the prognostic potential of circulating cell-free (CF…